Intelligent Investor

Apollo Consolidated Limited (ASX: AOP) - Announcements

DELISTED - Current share price for AOP : $0.610

ASX company news and announcements for Apollo Consolidated Limited (AOP) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Apollo Consolidated Limited (AOP) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Apollo Consolidated Limited (AOP), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Apollo Consolidated Limited (AOP)

Market Cap ($m) Headline Announcement date/time + Price at ann'ment + Current price + Price
7D Avg
Gain/Loss
- Needle-free psoriasis treatment outperforms competitors 17 Oct 2006 12:14PM $0.490 $0.610 $0.610 risen by 24.49%
- Apollo's Diabetes Breakthrough 25 Sep 2006 11:28AM $0.340 $0.610 $0.610 risen by 79.41%
- Preliminary Final Report 17 Aug 2006 6:17PM n/a $0.610 $0.610 n/a
- Commitments Test Entity - Fourth Quarter Report 28 Jul 2006 1:48PM n/a $0.610 $0.610 n/a
- Transdermal delivery breakthrough: needle-free biologics 3 Jul 2006 11:10AM $0.380 $0.610 $0.610 risen by 60.53%
- Initiates efficacy study on oral delivery of proteins 22 Jun 2006 11:37AM $0.390 $0.610 $0.610 risen by 56.41%
- Commitments Test Entity - Third Quarter Report 28 Apr 2006 11:11AM n/a $0.610 $0.610 n/a
- Reports positive results in Phase 1b psoriasis trial 22 Mar 2006 10:29AM $0.680 $0.610 $0.610 fallen by 10.29%
- Half Yearly Report/Half Year Accounts 15 Mar 2006 3:28PM $0.700 $0.610 $0.610 fallen by 12.86%
- Bill Moss invests $2m in Appollo Life Sciences & joins board 7 Mar 2006 11:28AM $0.550 $0.610 $0.610 risen by 10.91%
- Commitments Test Entity - Second Quarter Report 31 Jan 2006 12:44PM n/a $0.610 $0.610 n/a
- Phase 1b Psoriasis Trial Update 23 Jan 2006 2:40PM n/a $0.610 $0.610 n/a
- Produces Range of Protein Detection Kits 9 Dec 2005 2:18PM $0.600 $0.610 $0.610 risen by 1.67%
- Enters US$400m R&D reagents market 28 Nov 2005 2:43PM $0.600 $0.610 $0.610 risen by 1.67%
- Commitments Test Entity - First Quarter Report 31 Oct 2005 12:13PM n/a $0.610 $0.610 n/a
- Clinical Trial for Psoriasis Treatment Commences 18 Oct 2005 1:07PM $0.590 $0.610 $0.610 risen by 3.39%
- Apollo grows with acquisition 27 Sep 2005 1:15PM n/a $0.610 $0.610 n/a
- Apollo's human-expressed Interleukin2 outperforms competitor 1 Sep 2005 2:23PM $0.690 $0.610 $0.610 fallen by 11.59%
- Preliminary Final Report & Annual Report 29 Aug 2005 6:27PM n/a $0.610 $0.610 n/a
- Blood vessel forming protein outperforms competitor 9 Aug 2005 2:55PM $0.770 $0.610 $0.610 fallen by 20.78%
- Adds 10 more proteins to its library: Total 60 27 Jul 2005 2:33PM n/a $0.610 $0.610 n/a
- Admission to Official List 28 Jun 2005 5:39PM n/a $0.610 $0.610 n/a

551 - 572 of 572 results

Page 23 of 23

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© 2017 Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.